Compare Johnson & Johnson (JNJ) vs Ross Stores, Inc. (ROST) Price & Performance

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

Ross Stores (ROST) trades at $235.36, up 0.87% with strong technical and fundamental momentum. The stock shows bullish moving averages and recent earnings beats, with Q1 2026 EPS of $2.02 exceeding expectations by 17%. Revenue growth accelerated to $21.13B in 2025, while net income margin improved to 9.74%. Analyst sentiment remains positive with a $259 consensus target, supported by robust store expansion and customer acquisition trends noted in recent media coverage.

Outlook is favorable given consistent earnings outperformance and high ROE of 38.98%, though valuation multiples like P/E of 32.6 suggest premium pricing. Key risks include consumer spending sensitivity and competitive pressures in off-price retail. Institutional ownership trends and technical support near $232 provide a cushion for near-term stability.